This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

ChromaDex® Corp. Names Co-founder Frank Jaksch CEO & President

IRVINE, Calif., June 12, 2012 /PRNewswire/ --  ChromaDex Corporation (OTCBB: CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, animal health, food & beverage, cosmetic and pharmaceutical industries, announced today its co-founder and Chief Scientific Officer, Frank Jaksch, has been named CEO and President following the resignation of Jeffrey Himmel as CEO and President. Debra Heim has also chosen to resign as the company's COO and President of the Consumer Products Division.


Investor Dr. Phillip Frost commented on the announcement, saying, "I am grateful for Mr. Himmel's service to the company and respect his decision to return to his previous interests. I have complete confidence in the ability of Frank Jaksch to expand the analytical services and reference standards business while leading the company in the continued early-stage discovery and subsequent commercialization of natural products for health."

"While I have decided to step down as CEO of ChromaDex to resume my role as Chairman of the Himmel Group, I believe in ChromaDex's technology pipeline and future prospects," said Himmel. 

Jaksch, age 43, co-founded ChromaDex in 1999 . Under his previous leadership as CEO, ChromaDex developed a strong natural products and services business, expanded into international markets and built an impressive roster of Fortune 500 customers. 

"Having co-founded and spent more than a decade at ChromaDex, there has never been a time when I have had more enthusiasm for the company's potential for growth," said Jaksch. "I believe our legacy business remains strong and is poised to expand. I am most excited about our current efforts to develop novel compounds backed by intellectual property and human clinical studies, all with the aim of bringing healthy solutions for living to customers."

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs